Silver Book Fact

One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.

Holloway, Robert G. et al. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial. Arch Neurol. 2004; 61(7): 1044-53. http://archneur.ama-assn.org/cgi/content/full/61/7/1044

Reference

Title
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial
Publication
Arch Neurol
Publication Date
2004
Authors
Holloway, Robert G. et al.
Volume & Issue
Volume 61, Issue 7
Pages
1044-53
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The U.S. Food and Drug Administration has approved five drugs that temporarily improve Alzheimer’s disease symptoms.  
  • Deep brain stimulation, an electrical signal delivered deep inside the brain, provides significant symptomatic relief for Parkinson’s patients whose medication is no longer effective.  
  • Based on rates of admission in 1998, delaying admission of Alzheimer’s patients to nursing homes by 1 month could save as much as $1.12 billion a year.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 Medicare costs for people with the disease would be…  
  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…